2. (Original) The method of claim 1, wherein said therapeutic radioisotope is selected from the group consisting of alpha and beta emitters.

3. (Original) The method of claim 2, wherein said therapeutic radioisotope is a beta emitter.

4. (Original) The method of claim 3, wherein said beta emitter is ^{90}Y.

5. (Currently amended) The method of claim 1, wherein said protein or peptide is an antibody or antibody fragment.

6. (Original) The method of claim 4, wherein said sufficient incubation time is less than about eight minutes.

7. (Original) The method of claim 6, wherein said sufficient incubation time is between about 30 seconds to about five minutes.

8. (Original) The method of claim 1, wherein said chelator is a bifunctional chelator selected from the group consisting of MX-DTPA, phenyl-DTPA, benzyl-DTPA, CHX-DTPA, DOTA and derivatives thereof.

9. (Original) The method of claim 8, wherein said chelator is MX-DTPA.

10. (Original) The method of claim 4 wherein said amiable conditions refer to acceptable temperature, pH and buffer conditions.

11. (Original) The method of claim 10, wherein said acceptable temperature ranges from about 25°C to about 50°C.

12. (Original) The method of claim 10, wherein said acceptable pH ranges from about 3 to about 6.

13. (Original) The method of claim 10, wherein said acceptable buffer is an acetate buffer.

14. (Original) The method of claim 13, wherein said buffer is sodium acetate is at a concentration of between about 10 and about 1000 mM.

15. (Original) The method of claim 10, where said acceptable buffer includes a benign radioprotectant.

16. (Original) The method of claim 15, wherein said benign radioprotectant is ascorbate.

17. (Canceled)

18. (Original) The method of claim 1, wherein said binding specificity is at least 70%.

19. (Canceled by the reply filed April 11, 2003)

20-48. (Canceled by the application transmittal letter filed July 28, 2000)

49. (New) The method of claim 6, wherein said sufficient incubation time is about three minutes.

50. (New) The method of claim 6, wherein said sufficient incubation time is about five minutes.

51. (New) The method of claim 4, wherein said sufficient incubation time is about ten minutes.

52. (New) The method of claim 1, wherein a level of radioincorporation of at least about 96 % is achieved.

53. (New) The method of claim 1, wherein a level of radioincorporation of at least about 97 % is achieved.

54. (New) The method of claim 1, wherein a level of radioincorporation of at least about 98 % is achieved.

55. (New) The method of claim 1, wherein a level of radioincorporation of at least about 99 % is achieved.

56. (New) The method of claim 5, wherein the protein or peptide is an antibody fragment selected from the group consisting of Fab, $F(ab')_2$, and Fv fragments.

57. (New) The method of claim 5, wherein the protein or peptide is a therapeutic antibody or antibody fragment.

58. (New) The method of claim 57, wherein the protein or peptide binds specifically to CD20.

59. (New) The method of claim 57, wherein the protein or peptide is an antibody fragment selected from the group consisting of Fab, $F(ab')_2$, and Fv fragments.

60. (New) The method of claim 1, wherein the binding specificity is at least 50 %.

61. (New) The method of claim 1, wherein the binding specificity is at least 80 %.